Silexion Therapeutics Corp (SLXN): who owns it and who trades it
As of Nov 9, 2026, SLXN insiders reported 1 open-market sale worth $31K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mitchell Shirvan (CSO and CDO), with $31K.
Latest filing Nov 9, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, SLXN insiders reported $0 of open-market purchases and $31K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Mitchell Shirvan | CSO and CDO | Sale | 22,818 | $1.36 | $31K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mitchell Shirvan | CSO and CDO | – | $31K | Mar 26, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SLXN short interest
Low short interest. 1.5% of SLXN shares are sold short: about 1 share in 68. Over the last 12 reports the number of shares short went down 48%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 82,127 SLXN shares were sold short, 1.5% of the shares outstanding, down 49.5% from the report before. At the average daily volume of 1.49M shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 82,127 | 1.48% | -50% | 1.49M | 1.0 |
| Oct 15, 2026 | 162,704 | 2.93% | -97% | 1.60M | 1.0 |
| Sep 30, 2026 | 4.93M | 88.59% | +1964% | 40.44M | 1.0 |
| Sep 15, 2026 | 238,617 | 4.29% | +1546% | 15.57M | 1.0 |
| Aug 31, 2026 | 14,501 | 0.26% | -88% | 257,490 | 1.0 |
| Aug 14, 2026 | 119,287 | 2.15% | +460% | 927,154 | 1.0 |
| Jul 31, 2026 | 21,284 | 0.64% | +63% | 111,194 | 1.0 |
| Jul 15, 2026 | 13,090 | 0.39% | -5% | 21,092 | 1.0 |
| Jun 30, 2026 | 13,737 | 0.41% | -17% | 118,248 | 1.0 |
| Jun 15, 2026 | 16,557 | 0.50% | -89% | 233,740 | 1.0 |
| May 29, 2026 | 154,973 | 4.65% | -3% | 3.77M | 1.0 |
| May 15, 2026 | 159,027 | 4.77% | +380% | 476,377 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Silexion Therapeutics company events
Silexion Therapeutics filed 33 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementFurther to its previous reports, as well as the approval of its shareholders received on October 26, 2026, on November 9, 2026, Silexion Therapeutics Corp, a Cayman Islands exempted company issued a press release announcing a prospective 1-for-24 reverse share split of all of its issued and… Filing
- Oct 26, 2026VoteReported shareholder vote results. Filing
- Sep 30, 2026AnnouncementShared information with investors. Filing
- Sep 29, 2026AgreementSilexion Therapeutics Corp entered into an inducement offer letter agreement with certain holders of 3,216,928 of the Company’s existing series E warrants to purchase 3,216,928 of the Company’s ordinary shares, par value $0.135 per share, which were issued in the Company’s public offering completed… Filing
- Sep 28, 2026AnnouncementShared information with investors. Filing
- Sep 25, 2026ListingSilexion Therapeutics Corp received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC notifying the Company that, for the 30 consecutive business days preceding the letter, the closing bid price of the Company’s ordinary shares, par value $0.135 per share, was below… Filing
- Sep 25, 2026VoteReported shareholder vote results. Filing
- Aug 21, 2026ListingSilexion Therapeutics Corp, a Cayman Islands exempted company received a delisting notice from the Nasdaq Listing Qualifications Department in respect of a listing deficiency relating to our non-compliance with the minimum shareholders’ equity requirement for continued listing on The Nasdaq Capital… Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Aug 13, 2026AnnouncementAs previously reported, on May 28, 2026, the board of directors of Silexion Therapeutics Corp effected a 1-for-10 reverse share split of all of the Company’s issued and outstanding, and authorized but unissued, ordinary shares. Filing
- Aug 13, 2026AgreementSilexion Therapeutics Corp offered and sold in a public offering on a best efforts basis, and on August 13, 2026, Silexion consummated the Offering with respect to, (i) 2,028,619 of the Company’s ordinary shares, par value $0.135 per share, (ii) 1,817,542 pre-funded warrants to purchase 1,817,542… Filing
- Aug 10, 2026AnnouncementShared information with investors. Filing
- Aug 4, 2026AnnouncementShared information with investors. Filing
- Aug 3, 2026AnnouncementAs previously disclosed in a Current Report on Form 8-K filed by Silexion Therapeutics Corp with the Securities and Exchange Commission on July 31, 2026, Professor Amnon Peled notified the Company’s Board of Directors on July 30, 2026 of his resignation from the Board and all committees on which he… Filing
- Jul 31, 2026LeadershipProfessor Amnon Peled notified the Board of Directors of Silexion Therapeutics Corp of his resignation from his position as a member of the Board, for personal reasons, effective as of August 1, 2026. Filing
- Jul 29, 2026AnnouncementShared information with investors. Filing
- Jul 21, 2026VoteReported shareholder vote results. Filing
- May 29, 2026AnnouncementThe information set forth in Items 3.03 and 5.03 is hereby incorporated by reference into this Item 8.01. Filing
- May 26, 2026AnnouncementFurther to its previous reports, as well as the approval of its shareholders received on May 5, 2026, on May 26, 2026, Silexion Therapeutics Corp, a Cayman Islands exempted company issued a press release announcing a prospective 1-for-10 reverse share split of all of its issued and outstanding, and… Filing
- May 18, 2026ResultsReleased financial results. Filing
- May 15, 2026AgreementSilexion Therapeutics Corp entered into an inducement offer letter agreement with certain holders of 1,995,092 of the Company’s existing warrants to purchase 1,995,092 of the Company’s ordinary shares, par value $0.0135 per share. Filing
- May 14, 2026AnnouncementShared information with investors. Filing
- May 13, 2026AnnouncementShared information with investors. Filing
- May 5, 2026VoteReported shareholder vote results. Filing
- Apr 28, 2026AnnouncementShared information with investors. Filing
- Mar 25, 2026LeadershipThe Board of Directors of Silexion Therapeutics Corp removed Ilan Levin from his position as a member of the Board, effective immediately. Filing
- Mar 24, 2026AnnouncementShared information with investors. Filing
- Mar 23, 2026VoteReported shareholder vote results. Filing
- Feb 3, 2026AnnouncementShared information with investors. Filing
- Jan 6, 2026AnnouncementShared information with investors. Filing
- Dec 16, 2025AnnouncementShared information with investors. Filing
- Dec 2, 2025AnnouncementShared information with investors. Filing
- Nov 25, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Silexion Therapeutics financials
Questions about Silexion Therapeutics Corp (SLXN) stock
Are SLXN insiders buying or selling?
In the last 12 months, SLXN insiders reported no open-market purchases and 1 sale worth $31K. The latest trade was on Mar 26, 2026. See every trade.
What is the short interest in SLXN?
As of Oct 30, 2026, 82,127 SLXN shares were sold short, 1.5% of the shares outstanding, down 49.5% from the report before. At the average daily volume of 1.49M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.